Liberate-OLE

Liberate-OLE

The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly dosing of subcutaneous LIB003 300 mg administered in patients with CVD or at high risk for CVD on stable diet and oral LDL-C lowering drug therapy who completed one of the LIB003 Phase 3 base studies.

Please use this link for further information:

Primary Investigator: Dean Kereiakes